Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction

C. K. Deniston, J. Salogiannis, S. Mathea, D. M. Snead, I. Lahiri, M. Matyszewski, O. Donosa, R. Watanabe, J. Böhning, A. K. Shiau, S. Knapp, E. Villa, S. L. Reck-Peterson & A. E. Leschziner

This is a PDF file of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting. Nature is providing this early version of the typeset paper as a service to our authors and readers. The text and figures will undergo copyediting and a proof review before the paper is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

Cite this article as: Deniston, C. K. et al. Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction. Nature https://doi.org/10.1038/s41586-020-2673-2 (2020).
Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction

C. K. Deniston1,2, J. Salogiannis1,2, S. Mathea1,2, D. M. Snead1, I. Lahiri1,2, M. Matyszewski1, O. Donosa3, R. Watanabe4, J. Böhning5, A. K. Shiah6, S. Knapp1, E. Villa7, S. L. Reck-Peterson1,2,9 & A. E. Leschziner1,2,10

Leucine-rich repeat kinase 2 (LRRK2) is the most commonly mutated gene in familial Parkinson’s disease (PD) and is also linked to its idiopathic form. LRRK2 is proposed to function in membrane trafficking and co-localizes with microtubules. Despite LRRK2’s fundamental importance for understanding and treating PD, there is limited structural information on it. Here we report the 3.5Å structure of the catalytic half of LRRK2, and an atomic model of microtubule-associated LRRK2 built using a reported 14Å cryo-electron tomography in situ structure. We propose that the conformation of LRRK2’s kinase domain regulates its microtubule interaction, with a closed conformation favouring oligomerization on microtubules. We show that the catalytic half of LRRK2 is sufficient for filament formation and blocks the motility of the microtubule-based motors kinesin-1 and cytoplasmic dynein-1 in vitro. Kinase inhibitors that stabilize an open conformation relieve this interference and reduce LRRK2 filament formation in cells, while those that stabilize a closed conformation do not. Our findings suggest that LRRK2 can act as a roadblock for microtubule-based motors and have implications for the design of therapeutic LRRK2 kinase inhibitors.

LRRK2 is a large (288 kDa) multi-domain protein. Its amino-terminal half is comprised of repetitive protein interaction motifs (Armadillo, Ankyrin, and Leucine-Rich Repeats) and its carboxy-terminal catalytic half contains a Ras-like GTPase (Ras-of-Complex, or RoC domain), a kinase domain, and two other domains (C-terminal Of Roc, or COR, and WD40) (Fig. 1a). High-resolution structural data on LRRK2 is limited to bacterial homologues6,7 or isolated domains8,9, whereas low resolution full-length protein structures have been obtained using negative stain10 and cryo-electron microscopy (Cryo-EM)11. A recent study of LRRK2 bound to microtubules in cells using cryo-electron tomography (Cryo-ET) and subtomogram analysis led to a 14Å structure and proposed model of the catalytic half of LRRK2.

LRRK2’s interaction with microtubules is linked to disease as four of the five major PD-causing mutations (Fig. 1a) enhance microtubule binding, which results in in robust insect cell expression and well-behaved protein (Extended Data Fig. 1b, c). This construct comprises the RoC, COR, kinase and WD40 domains of LRRK2 (Fig. 1a), which we refer to as LRRK2RCKW. The COR domain was previously defined as consisting of two subdomains, COR-A and COR-B.

We determined a 3.5Å structure of LRRK2RCKW in the presence of GDP using cryo-EM (Fig. 1b, c and Extended Data Figs. 1 and 2). On our grids, we observed a mixture of monomers, dimers and head-to-tail trimer; we used the trimer to solve the structure (Fig. 1b and Extended Data Figs. 1 and 2). Although critical for reaching high resolution, the trimer is likely specific to the cryo-EM grid preparation as LRRK2RCKW is predominantly monomeric, with a smaller percentage of dimers, in solution (Extended Data Fig. 2n) and we only observed the trimer when preparing grids with high concentrations of LRRK2RCKW (see Methods). Due to flexibility, the RoC and COR-A domains were lower resolution in our structure (Fig. 1b, c). We improved this part of the map using signal subtraction and focused 3D classification and refinement (Fig. 1d, e, Extended Data Fig. 2a-d). The final model was generated using the signal subtracted maps of the RoC and COR-A domains, and then combined with the COR-B, kinase and WD40 domains from the trimer map (Fig. 1f, Extended Data Fig. 2e-m and Supplementary Video 1). Our model fits well into an 8.1Å reconstruction we obtained of a LRRK2RCKW monomer (Fig. 1g, and see Extended Data Fig. 6), indicating that trimer formation does not cause major structural changes in the protein.

1 Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA. 2 Howard Hughes Medical Institute, Chevy Chase, MD, USA. 3 Institute of Pharmaceutical Chemistry, Goethe-Universität, Frankfurt, Germany. 4 Present address: Department of Biological Sciences, Indian Institute of Science Education and Research Mohali, Mohali, Punjab, India. 5 Division of Biological Sciences and Molecular Biology Section, University of California San Diego, La Jolla, CA, USA. 6 Present address: La Jolla Institute for Immunology, La Jolla, CA, USA. 7 Division of Biological Sciences, Cell and Developmental Biology Section, University of California San Diego, La Jolla, CA, USA. 8 Small Molecule Discovery Program, Ludwig Institute for Cancer Research, La Jolla, CA, USA. 9 Division of Biological Sciences, Molecular Biology Section, University of California San Diego, La Jolla, CA, USA. 10 These authors contributed equally: C. K. Deniston, J. Salogiannis, S. Mathea.

* e-mail: sreckpeterson@ucsd.edu; aleschziner@ucsd.edu

Published online: 19 August 2020

https://doi.org/10.1038/s41586-020-2673-2

Received: 10 November 2019
Accepted: 12 August 2020

https://www.nature.com/
ACCELERATED
patterns of WT and I2020T LRRK2RCKW are different, with the I2020T for the formation of microtubule-associated filaments. The layer line for this effect will require high-resolution structures of the filaments formed by WT and I2020T LRRK2.

Previously, integrative modelling was used to build a model into the in situ structure of microtubule-associated LRRK2. This model indicated that the well-resolved Cryo-ET density closest to the microtubule was comprised of the RoC, COR, Kinase and WD40 domains and gave orientation ensembles for each domain that are in good agreement with our high-resolution structure of LRRK2RCKW (Extended Data Fig. 4a). Here, we built an atomic model of the microtubule-bound LRRK2 filaments by combining our 3.5Å structure of LRRK2RCKW with the 3.5Å in situ structure of microtubule-associated LRRK2 (Extended Data Fig. 4b-f). This revealed that the LRRK2RCKW structure is sufficient to account for the density seen in the in situ structure (Fig. 2c), in agreement with our ability to reconstitute microtubule-associated LRRK2RCKW filaments in vitro (Fig. 2b), and with the earlier modelling.

Although our LRRK2RCKW structure fits the overall shape of the cryo-ET map, there were significant clashes at the COR domain interfaces (Fig. 2d). Since the kinase in our LRRK2RCKW structure is in an open conformation, we hypothesized that filament formation might require LRRK2’s kinase to be in a closed conformation. To test this, we modelled a kinase-closed LRRK2RCKW (Extended Data Fig. 2e and Extended Data Fig. 4g-j) and used it to rebuild the LRRK2 filament. The kinase-closed LRRK2RCKW model resolved more than 80% of the backbone clashes we had observed with our kinase-open LRRK2RCKW structure (Fig. 2c, d, f, g). A closed conformation for the kinase was also proposed by the integrative modelling. Given this data, we hypothesize that the conformation of LRRK2 controls its ability to oligomerize on microtubules, with a closed kinase promoting oligomerization and an open (inactive) one disfavouring it (Fig. 2h, i).

The LRRK2 filaments in our kinase-closed model are formed by two homotypic interactions: one is mediated by the WD40 domain, and the other by the COR-A and COR-B domains (Fig. 3a–d). Similar interfaces were reported based on the cryo-ET structure. We also solved structures of LRRK2RCKW dimers, using the same grids that yielded the 3.5Å structure of LRRK2RCKW (Extended Data Fig. 4b-f). This revealed that the LRRK2 RCKW structure (Fig. 2e, f) and Extended Data Figs. 5 and 6). The interface in the COR-mediated dimer of LRRK2RCKW differs from that reported for the C. tepidum Roco protein; while the GTPase domains interact directly in the dimer of LRRK2, the WD40 and COR/COR-mediated dimers, indicating that both interfaces mediate dimerization in the absence of microtubules (Fig. 3e, f and Extended Data Figs. 5 and 6). The interface in the COR-mediated dimer of LRRK2RCKW differs from that reported for the C. tepidum Roco protein; while the GTPase domains interact directly in the dimer of the bacterial protein, they are not involved in the dimerization interface we observed for LRRK2 (Extended Data Fig. 6c).

We built an independent model of a closed-kinase LRRK2RCKW by splitting our 3.5Å structure in half at the junction between the N- and C-lobes of the kinase, and fitting the fragments into our cryo-EM map of a WD40/WD40 dimer obtained in the presence of a LRRK2-specific Type I kinase inhibitor, MLi-222,23, which is predicted to stabilize the kinase closed conformation (Extended Data Fig. 7a-c). We then docked this closed-kinase model (Extended Data Fig. 7c) into the cryo-EM maps of WD40- and COR/COR-mediated dimers obtained in the presence of MLi-2 to generate molecular models of both dimers (Extended Data Fig. 7d, e). We aligned these models to build a polymer in silico. This resulted in a right-handed helix with the same general geometric properties seen in the cellular LRRK2 filaments, indicating that those properties are largely encoded in the structure of LRRK2RCKW itself (Fig. 3g, h, and Extended Data Fig. 7d). Docking the same two halves of LRRK2RCKW into the cryo-EM map of a monomer we obtained in the absence of inhibitors or ATP led to a structure similar to our 3.5Å structure obtained from trimeric, further confirming that trimer formation does not alter the conformation of LRRK2RCKW (Extended Data Fig. 7g, h).

**Article**

**LRRK2RCKW** adopts an overall J-shape, with the WD40, kinase and COR-B domains arranged along one axis, and COR-A and Roco turning around back towards the kinase. This brings the COR-A and tightly associated Roco domain into close proximity to the kinase’s C-lobe (Fig. 1f, and Supplementary Video 1). This arrangement likely underpins the crosstalk between LRRK2’s kinase and GTPase. Part of the FERM domain in the FAK-FERM complex approaches the FAK C-lobe in a similar way7 (Extended Data Fig. 3a, b). The RoC, COR, A and COR-B domains are arranged as seen in crystal structures of LRRK2 bacterial homologues8–10. The N-lobe of the kinase domain, in particular its αC helix, forms an extensive interaction with the COR-B domain, with COR-B occupying a location similar to Cylcin A in CDK2-Cyclin A7 (Extended Data Fig. 3a, c).

The kinase in our LRRK2RCKW structure is in an open, inactive conformation. Its activation loop contains the site of two familial PD mutations (G2019S and I2020T) and is disorder beyond G2019 (Fig. 1h, Extended Data Fig. 2h, and Supplementary Video 2). R1441 and Y1699 are the sites of three other familial PD mutations and are located at the RoC-COR-B interface (Fig. 1h, Extended Data Fig. 2j, and Supplementary Video 2). Given that the kinase and GTPase interact with each other via the COR domain, it is possible that these mutations, located at the interface between the GTPase and COR-B, alter the conformational landscape of LRRK2 in response to ligands and/or regulatory signals and thus affect the cross-talk between LRRK2’s catalytic domains.

A unique feature of LRRK2 is a 28-amino acid α-helix located at its extreme C-term, following the WD40 domain (Fig. 1i, j, and Supplementary Video 3). While a number of other kinases have α-helices in the same general location, none form interactions as extensive as those observed in LRRK2 (Fig. 1i, j, Extended Data Fig. 3d-i). Deletion of this helix resulted in an insoluble protein (Extended Data Fig. 1a, b). A residue near its end (T2524) is a known phosphorylation site for LRRK2. Given the close proximity between T2524 and the N-lobe of the kinase domain, as well as the adjacent COR-B domain, we hypothesize that phosphorylation of this residue may play a role in regulating the kinase. Since the last two residues of the C-terminal helix are disordered in the in situ structure of microtubule-associated LRRK2, it is possible that conditions exist where these regions become ordered and turn the C-terminal helix into a scaffolding element that connects COR-B, the kinase, and the WD40 domains.

We modelled the Leucine-Rich Repeats (LRR) into LRRK2RCKW by using a crystal structure of the LRR, RoC, and COR domains of *C. tepidum* Roco protein7 (Extended Data Fig. 3l-p). In our model, the LRR wraps around the N-lobe of the kinase and approaches the C-lobe, placing the Roco protein7 (Extended Data Fig. 3l-p). In our model, the LRR wraps around the N-lobe of the kinase and approaches the C-lobe, placing the LRR into a scaffolding element that connects COR-B, the kinase, and the WD40 domains.

We modelled the Leucine-Rich Repeats (LRR) into LRRK2RCKW by using a crystal structure of the LRR, RoC, and COR domains of *C. tepidum* Roco protein7 (Extended Data Fig. 3l-p). In our model, the LRR wraps around the N-lobe of the kinase and approaches the C-lobe, placing the LRR into a scaffolding element that connects COR-B, the kinase, and the WD40 domains.

**Model of microtubule-bound filaments**

Recently, a 14Å structure of microtubule-associated filaments of full-length LRRK2 (carrying the filament-promoting I2020T mutation)11 was determined using in situ cryo-ET and subtomogram analysis12 (Fig. 2a). The LRRK2 filaments formed on microtubules are right-handed1. Because microtubules are left-handed and no strong density connected the LRRK2 filament to the microtubule surface, it is unknown if LRRK2’s microtubule interaction is direct. To address this, we combined purified microtubules and LRRK2RCKW, either WT or I2020T, and imaged them by cryo-EM. Both WT and I2020T LRRK2RCKW bound to microtubules, and diffraction patterns calculated from the images revealed layer lines consistent with the formation of ordered filaments (Fig. 2b). Thus, the interaction between LRRK2 and microtubules is direct and the catalytic C-terminal half of LRRK2 is sufficient for the formation of microtubule-associated filaments. The layer line patterns of WT and I2020T LRRK2RCKW are different, with the I2020T diffraction pattern having an additional layer line of lower frequency, indicating longer-range order in the filaments (Fig. 2b). This is consistent with the observation that the I2020T mutation promotes microtubule association by LRRK2 in cells.12 Understanding the structural basis for this effect will require high-resolution structures of the filaments formed by WT and I2020T LRRK2.
These data, along with the apparent lack of any residue-specific interactions between LRRK2 and the microtubule lattice, suggest that the microtubule may provide a surface for LRRK2 to oligomerize on using interfaces that exist in solution, thus explaining the symmetry mismatch between the microtubule and the LRRK2 filament. Consistent with this, the surface charge of the microtubule facing the LRRK2\textsuperscript{RCKW} filament is acidic, while there are basic patches on the LRRK2\textsuperscript{RCKW} filament facing the microtubule (Extended Data Fig. 7i). The unstructured C-terminal tails of α- and β-tubulin, which were not included in the surface charge calculations, are also acidic.

**LRRK2\textsuperscript{RCKW} inhibits kinesin and dynein**

To test our hypothesis that the conformation of LRRK2's kinase domain regulates its interaction with microtubules, we needed a sensitive assay to measure the association of LRRK2\textsuperscript{RCKW} with microtubules and a means to control the conformation of its kinase. We monitored microtubule association by measuring the effect of LRRK2\textsuperscript{RCKW} on microtubule-based motor motility. We used a truncated human kinase-1, Ki67 ("kinase")\textsuperscript{4}, which moves towards the microtubule plus end, and the activated human cytoplasmic dynein-1/ dynactin/ ninein-like complex ("dynein")\textsuperscript{3}, which moves in the opposite direction. Using single-molecule in vitro motility assays (Fig. 4a), we found that low nanomolar concentrations of LRRK2\textsuperscript{RCKW} inhibited both kinesin and dynein movement, with near complete inhibition at 25 nM LRRK2\textsuperscript{RCKW} (Fig. 4b, c and Extended Data Fig. 8a, b). We hypothesized that LRRK2\textsuperscript{RCKW} was acting as a roadblock for the motors. In agreement with this, the distance that single kinesins moved (run length) was reduced (Fig. 4d), while their velocity remained relatively constant (Fig. 4e). We obtained similar results with dynein (Fig. 4f). Other microtubule-associated proteins, such as MAP2 and Tau, also inhibit kinesin, but not dynein\textsuperscript{26,27}, likely due to dynein's ability to sidestep on the microtubule\textsuperscript{30}. LRRK2's unusual ability to inhibit dynein may be a consequence of it forming oligomers that cannot be overcome by sidestepping.

We also tested the inhibition of kinesins by I2020T LRRK2\textsuperscript{RCKW}, which promotes filament formation when overexpressed in cells\textsuperscript{12,19} (I2020T LRRK2\textsuperscript{RCKW} inhibited kinesin to a similar extent as WT LRRK2\textsuperscript{RCKW} (Extended Data Fig. 8c, d)). Given that in vitro reconstituted filaments of I2020T LRRK2\textsuperscript{RCKW} show longer range order compared with WT LRRK2\textsuperscript{RCKW} (Fig. 2b), it is possible that the high sensitivity of the single-molecule motility assays does not allow us to distinguish differences in oligomer length and/or stability between WT and I2020T LRRK2\textsuperscript{RCKW}.

**Type II inhibitors rescue the motors**

Our hypothesis predicts that the closed conformation of LRRK2's kinase domain will favour LRRK2's oligomerization on microtubules. Conversely, it predicts that conditions that stabilize the kinase in an open conformation will prevent oligomerization and thus decrease microtubule binding by LRRK2\textsuperscript{RCKW}, resulting in relief of LRRK2\textsuperscript{RCKW}-dependent inhibition of kinesin and dynein motility. To test these predictions, we searched for a Type II kinase inhibitor that binds tightly to LRRK2 with structural evidence that it stabilizes an open kinase conformation. We selected Ponatinib, which has a K\textsubscript{i} for LRRK2 of 31 nM\textsuperscript{31}, and crystal structures show it bound to RIKP2\textsuperscript{22} and IRAK4 \textsuperscript{24} (PDB: GEG9) in open conformations (Extended Data Fig. 9a). Ponatinib inhibited LRRK2\textsuperscript{RCKW}'s ability to phosphorylate Rab\textsubscript{8A}\textsuperscript{34} (Extended Data Fig. 9f).

As our hypothesis predicted, Ponatinib rescued kinesin motility in a dose-dependent manner at concentrations of LRRK2\textsuperscript{RCKW} (25 nM) that had resulted in almost complete inhibition of kinesin (Fig. 5a, Extended Data Fig. 9g-j). We observed similar effects with GZD-824, a chemically-related Type II kinase inhibitor\textsuperscript{35} (Fig. 5a and Extended Data Fig. 9i, j). Our hypothesis also predicted that kinase inhibitors that stabilize the closed form of the kinase would not rescue the motors and might enhance the inhibitory effect of LRRK2\textsuperscript{RCKW} by increasing its ability to form filaments on microtubules. Indeed, MLi-2\textsuperscript{22,23} and another LRRK2-specific Type I inhibitor, LRRK2-IN-1\textsuperscript{34}, which are expected\textsuperscript{22,35} to stabilize a closed conformation of the kinase (Extended Data Fig. 9b-e), further enhanced the inhibitory activity of LRRK2\textsuperscript{RCKW} on kinases (Fig. 5a). Dynein motility was also rescued by Ponatinib and GZD-824, but not by MLi-2 or LRRK2-IN-1 (Fig. 5b, Extended Data Fig. 9i, k). Like Ponatinib, GZD-824, MLi-2 and LRRK2-IN-1 inhibited phosphorylation of Rab\textsubscript{8A} by LRRK2\textsuperscript{RCKW} (Extended Data Fig. 9f).

**GZD-824 reduces filaments in cells**

In cells, LRRK2 forms filaments that colocalize with a subset of microtubules and are sensitive to the microtubule depolymerizing drug nocodazole\textsuperscript{22}. This association is enhanced by the PD-linked mutations R1441C, R1441G, Y1699C and I2020T\textsuperscript{12,26} and by Type I kinase inhibitors\textsuperscript{34,35}. We tested our kinase conformation hypothesis in human 293T cells by determining if Type I and Type II kinase inhibitors had opposite effects on the formation of microtubule-associated LRRK2 filaments in cells. Consistent with previous findings\textsuperscript{34,35}, the Type I inhibitor MLi-2 enhanced LRRK2's microtubule association (Fig. 5c), suggesting that the closed conformation of the kinase favours binding to microtubules in cells. In contrast, we found that the Type II inhibitor GZD-824 reduced the filament-forming ability of overexpressed LRRK2 (I2020T) (Fig. 5d). This reduction in LRRK2 filament formation was not due to changes in LRRK2 protein expression levels or the overall architecture of the microtubule cytoskeleton (Extended Data Fig. 9i-n).

**Conclusions**

Here we reported the 3.5Å structure of the catalytic half of LRRK2 and used it, in combination with a 14Å cryo-ET structure of a microtubule-associated LRRK2 filament\textsuperscript{2}, to build an atomic model of these filaments. This modelling led us to hypothesize that the conformation of LRRK2's kinase controls its association with microtubules (Fig. 5e). Cryo-EM structures of LRRK2\textsuperscript{RCKW} dimers we obtained in the absence of microtubules showed that the same interfaces are involved in both dimerization and filament formation, and aligning them in silico resulted in a right-handed filament with similar properties to LRRK2 filaments observed in cells, suggesting that the ability of LRRK2 to form filaments is a property inherent to LRRK2, and specifically the RCKW domains. We propose that both the surface charge and geometric complementarity between the microtubule and LRRK2 promote the formation of LRRK2 filaments. It remains to be determined whether LRRK2\textsuperscript{RCKW} monomers or dimers are the minimal filament forming unit.

We tested our model that the conformation of LRRK2's kinase regulates microtubule association using kinase inhibitors expected to stabilize either the open (Type II) or closed (Type I) conformations of the kinase. In support of our model, Type II inhibitors relieved LRRK2\textsuperscript{RCKW} dependent inhibition of kinesin and dynein and reduced LRRK2 filament formation in cells, while Type I inhibitors failed to rescue motor motility and enhanced filament formation in cells. Importantly, our single-molecule motility assays showed that low nanomolar concentrations of LRRK2\textsuperscript{RCKW} negatively impact both kinases and dynein. At these low concentrations it is likely that LRRK2 would not form the long, highly ordered filaments and microtubule bundles observed in cells overexpressing the protein; instead, we hypothesize that at endogenous expression levels in cells LRRK2 forms short oligomers on microtubules.

What is the physiological role of non-pathogenic microtubule-associated LRRK2? Our data show that LRRK2 acts as a roadblock for microtubule-based motors in vitro. In cells, dynein and kinesin bind directly or indirectly to many Rab-marked cargos\textsuperscript{39–42}. Our data also show that the microtubule-associated form of LRRK2 has its...
kinase in a closed (and potentially active) conformation. Given this, microtubule-associated LRRK2 stalling of kinesin or dynein could increase the likelihood that LRRK2 phosphorylates cargo-associated Rabs\(^{13}\), modulating effector binding\(^{13}\) and resulting in changes in cargo dynamics. In support of this, the four PD mutations that enhance LRRK2 microtubule binding\(^{12}\) also show higher levels of Rab phosphorylation in cells than the G2019S mutant\(^{14}\), whose microtubule binding is not enhanced over wild-type LRRK2\(^{12}\).

Our data have important implications for the design of LRRK2 kinase inhibitors for therapeutic purposes. They predict that inhibitors that favour the closed conformation of the kinase will promote LRRK2 filament formation, thus blocking microtubule-based trafficking, while inhibitors that favour an open conformation of the kinase will not. These results should be taken into account to enhance therapeutically beneficial effects of LRRK2 kinase inhibition and to avoid potential unintended side effects.

Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41586-020-2673-2.
Fig. 1 | Cryo-EM structure of LRRK2<sub>2CXXW</sub>. **a**, Schematic of the construct used in this study. The N-terminal half of LRRK2, absent from our construct, is shown in dim colours. The same colour-coding of domains is used throughout the paper. The five major familial Parkinson’s Disease mutations and a Crohn’s Disease-linked mutation are indicated. **b**, **c**, 3.5 Å cryo-EM map (b) and local resolution (c) of the LRRK2<sub>2CXXW</sub> trimer, with one monomer highlighted. **d**, **e**, 3.8 Å cryo-EM map (d) and local resolution (e) of a LRRK2<sub>2CXXW</sub> monomer with improved resolution for the RoC and COR-A domains. **f**, Ribbon diagram of the atomic model of LRRK2<sub>2CXXW</sub>. **g**, 8.1 Å cryo-EM map of monomeric LRRK2<sub>2CXXW</sub> with the model in (f) docked in. **h**, Location of the Parkinson’s and Crohn’s Disease mutations listed in (a). **i, j**, Interface between the C-terminal helix and the kinase domain in LRRK2<sub>2CXXW</sub> with residues involved in electrostatic and hydrophobic interactions indicated.
Fig. 2 | Modelling the microtubule-associated LRRK2 filaments. a, 14Å cryo-ET map of a segment of microtubule-associated LRRK2 filament in cells. The microtubule is shown in blue and the LRRK2 filament in grey. b, Microtubule-associated LRRK2<sup>2<sup>x34</sup></sup> filaments reconstituted in vitro from purified components. (Top) Single cryo-EM images of a naked microtubule (left), and WT (centre) and I2020T (right) LRRK2<sup>2<sup>x34</sup></sup> filaments. (Bottom) Diffraction patterns (power spectra) calculated from the images above. White and hollow arrowheads indicate the layer lines corresponding to the microtubule and LRRK2<sup>2<sup>x34</sup></sup>, respectively. Scale bar: 20nm. c, Fitting of the LRRK2<sup>2<sup>x34</sup></sup> structure, which has its kinase in an open conformation, into the cryo-ET map. d, Atomic model of the LRRK2<sup>2<sup>x34</sup></sup> filaments from (c). The white circle highlights the filament interface mediated by interactions between COR domains, where clashes are found. e, Superposition of the LRRK2<sup>2<sup>x34</sup></sup> structure (colored by domains) and a model of LRRK2<sup>2<sup>x34</sup></sup> with its kinase in a closed conformation in blue. The dashed blue arrow indicates the closing of the kinase. f, Fitting of the closed-kinase model of LRRK2<sup>2<sup>x34</sup></sup> into the cryo-ET map. g, Atomic model of the closed-kinase LRRK2<sup>2<sup>x34</sup></sup> filaments (g) with a white circle highlighting the same interface as in (d). h, i, Cartoon representation of the two filament models, highlighting the clashes observed with open-kinase LRRK2<sup>2<sup>x34</sup></sup> (h) and resolved with the closed-kinase model (i). 82% of clashes were resolved using the closed-kinase LRRK2<sup>2<sup>x34</sup></sup> model (see Methods for details).
Fig. 3 | LRRK2<sup>2<sup>2<sup>CNX</sup></sup> forms WD40- and COR-mediated dimers outside the filaments. a–d. The filament model shown in Fig. 2j, k is shown here in grey, with either a WD40-mediated (a), or COR-mediated (c) LRRK2<sup>2<sup>2<sup>CNX</sup></sup> dimer highlighted with domain colours. The corresponding molecular models are shown next to the cartoons (b, d). e, f. Cryo-EM reconstructions of LRRK2<sup>2<sup>2<sup>CNX</sup></sup> dimers obtained in the absence of inhibitor (“Apo”), or in the presence of MLi-2. For each reconstruction, two orientations of the map are shown: down the twofold axis at the dimerization interface (left), which matches the orientation of the models shown in (b, d), and perpendicular to it (right). The top row shows the cryo-EM map and the bottom row a transparent version of it with a model docked in. g. Molecular models of the WD40-mediated and COR-mediated LRRK2<sup>2<sup>2<sup>CNX</sup></sup> dimers obtained in the presence of MLi-2 (e, f) were aligned in alternating order. This panel shows the resulting right-handed helix. h. The helix has dimensions compatible with the diameter of a 12 protofilament microtubule (EMD-5192)<sup>44</sup>, which was the species used to obtain the cryo-ET map shown in Fig. 2a<sup>5</sup>, and has its RoC domains pointing towards the microtubule surface.
**Fig. 4 | LRRK2<sup>scxw</sup> inhibits the motility of kinesin and dynein.**

**a.** Schematic of the single-molecule motility assay.

**b, c.** The percentage (mean ± s.d.) of motile events per microtubule as a function of LRRK2<sup>scxw</sup> concentration for kinesin (b) and dynein (c). ****P < 0.0001 (Kruskal–Wallis test with Dunn’s posthoc for multiple comparisons for (b)) and ****P < 0.0001 (Mann–Whitney test) for (c).

**d.** Cumulative frequency distribution of kinesin run lengths as a function of LRRK2<sup>scxw</sup> concentration. Mean decay constants (tau) are shown. The 12.5 nM and 25 nM, but not 6.25 nM, conditions were significantly different (P < 0.0001) than the 0 nM condition (one-way ANOVA with Dunnett’s test for multiple comparisons using error generated from a bootstrapping analysis).

**e.** Velocity of kinesin as a function of LRRK2<sup>scxw</sup> concentration. Data are mean ± s.d. ****P < 0.0001 (one-way ANOVA with Dunn’s posthoc for multiple comparisons).

**f.** Cumulative frequency distribution of dynein run lengths as a function of LRRK2<sup>scxw</sup> concentration. Mean decay constants (tau) are shown. Data was resampled with bootstrapping analysis and was significant. P < 0.0001 (unpaired t-test with Welch’s correction using error generated from a bootstrapping analysis).
Fig. 5 | Type II, but not Type I, kinase inhibitors rescue kinesin and dynein motility and reduce LRRK2 filament formation in cells. a, b, Effects of different kinase inhibitors on LRRK2\textsuperscript{RCKW}’s inhibition of kinesin (a) and dynein (b) motility. Data shown is the percentage of motile events per microtubule (MT) as a function of LRRK2\textsuperscript{RCKW} concentration in the absence (DMSO) or presence of the indicated inhibitors (Ponatinib and GZD-824: 10 μM; MLi-2 and LRRK2-IN-1: 1 μM). Data are mean ± s.d. ***P < 0.001 and ****P < 0.0001 (Kruskal–Wallis test with Dunn’s posthoc for multiple comparisons within drug only). c, Treatment with MLi-2 (500 nM) for 2 h increases WT GFP-LRRK2 filament formation in 293T cells. Data are mean ± s.d. ****P = 0.0002 (Mann–Whitney test). d, Treatment with GZD-824 (5 μM) for 30 min decreases GFP-LRRK2 (I2020T) filament formation in 293 cells. Data are mean ± s.d. *P = 0.0133 and **P = 0.0012 (Kruskal–Wallis test with Dunn’s posthoc test for multiple comparisons). e, Schematic representation of our hypothesis. LRRK2’s kinase can be in an open or closed conformation. The different species we observed are represented in the rounded rectangles, but only monomers are shown on the microtubule for simplicity. Our model proposes that the kinase-closed form of LRRK2 favours oligomerization on microtubules.
For baculovirus expression, the DNA coding for wild-type LRRK2 residues 1327 to 2527 (taken from Mammalian Gene Collection) was PCR-amplified using the forward primer TACTTCCAATCCTAGAAAAGGTGTGCTTATAACGGAG and the reverse primer TATCCACCTTTACTGTCACCAAGATGTGTTCGTCATTTTCA. The T4 polymerase-treated amplicon was inserted into the expression vector pBbHb6H2b by ligation-independent cloning. According to Bac-to-Bac expression system protocols (Invitrogen), this plasmid was used for the generation of recombinant baculoviruses. For mammalian expression vectors, pDEST33-GFP-LRRK2 (WT) was adduced from Addgene (#25044) was used. pDEST33-GFP-LRRK2 (I2020T) was cloned using QuickChange site-directed mutagenesis (Agilent) with the forward primer AAGATTGCTGACTACGGCACTGCTCAGTACTGCTG and the reverse primer CAGCAGTACTGAGCAGTGATCTGACGAACTCT. pET17b-Kif5b(l-560)-GFP-His4 was obtained from Addgene (#15219). For pET28a-ZZ-TEV-Halo-NiL1 NiL2 NiN1 NiN2 were synthetized as previously described and inserted into a pET28a expression vector with a synthesized ZZ-TEV-Halo gBlock fragment (IDT) using Gibson assembly.

**LRRK2**<sup>3ckw</sup> expression and purification

The expression construct contained an N-terminal His-, Z-tag, cleavable with TEV protease (Extended Data Fig. 1a-c). For LRRK2<sup>3ckw</sup> purification, the pelleted SP cells were washed with PBS, resuspended in lysis buffer (50 mM HEPES pH 7.4, 500 mM NaCl, 20 mM imidazole, 0.5 mM TCEP, 5% glycerol, 5 mM MgCl<sub>2</sub>, 20 μM GDP) and lysed by sonication. The lysate was centrifuged and loaded onto a Ni-NTA (Qiagen) column. After vigorous rinsing with lysis buffer the His-tagged protein was eluted in lysis buffer containing 300 mM imidazole. Immediately thereafter, the eluate was diluted with a buffer containing no NaCl, in order to reduce the NaCl-concentration to 250 mM and loaded onto an SP sepharose column. His-, Z-TEV-LRRK2<sup>3ckw</sup> was eluted with a 250 mM to 2.5 M NaCl gradient and treated with TEV protease overnight to cleave the His-, Z-tag. Contaminating proteins, the cleaved tag, uncleaved protein and TEV protease were removed by another combined SP sepharose Ni-NTA step. Finally, LRRK2<sup>3ckw</sup> was concentrated and subjected to gel filtration in storage buffer (20 mM HEPES pH 7.4, 800 mM NaCl, 0.5 mM TCEP, 5% glycerol, 2.5 mM MgCl<sub>2</sub>, 20 μM GDP) using an AKTA Xpress system combined with a S200 gel filtration column. The final yield as calculated from UV absorbance was 1.2 mg LRRK2<sup>3ckw</sup>/L insect cell medium.

**SEC-MALS**

SEC-MALS experiments were performed using an AKTA microchromatography system hooked up to a Superdex 200 Increase 2.0x300 size exclusion chromatography column coupled in-line to a DAWN HELEOS II multichannel light scattering detector (Wyatt Technology) and an Optilab T-rEX refractive index detector (Wyatt Technology). SEC-MALS was performed in 50 mM Hepes pH 7.4, 200 mM NaCl, 0.5 mM TCEP, 5% glycerol, 5 mM MgCl<sub>2</sub>, and 20 μM GDP. For a typical sample, 50 μl of 7 μM LRRK2<sup>3ckw</sup> was injected onto the column. Molar mass was calculated using ASTRA 6 software, with protein concentration derived from the Optilab T-rEX. LRRK2<sup>3ckw</sup> used for SEC-MALS experiments contained an extra 16 residue N-terminal Gly-Ser linker sequence.

**Electron microscopy**

**Electron microscopy sample preparation and imaging of trimer data set.** Purified LRRK2<sup>3ckw</sup> was dialysed into a final buffer consisting of 20 mM HEPES pH 7.4, 800 mM NaCl, 0.5 mM TCEP, 5% glycerol, 2.5 mM MgCl<sub>2</sub> and 20 μM GDP and then diluted to a final concentration of 4 μM in the same buffer. We have only observed the trimer species when preparing grids with LRRK2<sup>3ckw</sup> at concentrations of 4 μM or above and for our “Apo” samples (that is, in the absence of inhibitors). This sample was applied to glow-discharged (20 μm for 30 s in a K100 Instrument) UltrAuFoil Holey Gold R 1.2/1.3 grids (Quantifoil). A Vitrobot (FEI) was then used to blot away excess sample and plunge freeze the grids in liquid ethane. Grids were stored in liquid nitrogen until imaging.

Cryo-EM data was collected at UCLA California NanoSystems Institute in a Titan Krios (FEI) operated at 300kV, equipped with a K2 Summit direct electron detector (Gatan) and a Quantum energy filter (Gatan). Automated data collection was performed using Leginon<sup>48</sup>. We recorded a total of 3,824 movies in “counting mode” at a dose rate of 6.65 electrons Å<sup>-2</sup> sec<sup>-1</sup> with a total exposure time of 8 s sub-divided into 200 frames, for a total of 40 frames. The images were recorded at a nominal magnification of 130,000 resulting in an object pixel size of 1.07Å. The defocus range of the data was -1μm to -1.8μm.

**Electron microscopy map and model generation of trimer data set.** We aligned the movie frames using UCSF MotionCor2<sup>49</sup>, using the dose-weighted frame alignment option. We estimated the CTF on dose-weighted images using GCTF version 1.06<sup>66</sup> as implemented in Appion<sup>50</sup> with per-particle CTF generation. Images having CTF fits worse that 5Å (as determined by GCTF) were excluded from further processing. Using this approach, 3,693 micrographs were kept for further processing. We selected particles from micrographs using FindEM<sup>51</sup> with projections of a trimeric LRRK2<sup>3ckw</sup> map, created from an initial Cryosparc ab initio model generation, serving as a reference. Particle picking was performed within the framework of Appion, resulting in a data set of 836,956 particles.

We carried out subsequent processing first in Relion 3.0<sup>52</sup> then in CryoSparc<sup>2</sup>. A series of 2D and 3D classifications were performed as shown in Extended Data Fig. If to generate the final map. The initial reference was created in a similar manner to those used for template picking, from an initial ab initio model generated in CryoSparc. All references were filtered to either 60Å (default in Relion) or 30Å (default in CryoSparc) before refinement processes. The final map, generated in Cryosparc using non-uniform refinement and while applying C3 symmetry, reached 3.47Å resolution. Initial 2D classifications used binned data (4.28Å pixel<sup>-1</sup>) while all subsequent 3D classifications and refinement steps used unbinned images (1.07 Å pixel<sup>-1</sup>).

In order to improve the density corresponding to the RoC and COR-A domains, a second map was generated following a different processing scheme, which used signal subtraction and is shown in Extended Data Fig. 2a. The final refinement led to a 3.5Å map of LRRK2<sup>3ckw</sup>. All the steps used unbinned images (1.07 Å pixel<sup>-1</sup>). The resolutions of the cryo-EM maps, here and below, were estimated from Fourier Shell Correlation (FSC) curves calculated using the gold-standard procedure and the resolutions are reported according to the 0.143 cutoff criterion<sup>46</sup>. FSC curves were corrected for the convolution effects of a soft mask applied to the half maps by high-resolution phase randomization<sup>57</sup>. For display and analysis purposes, we sharpened the maps with automatically estimated negative B factors from Relion or CryoSparc.

We built the LRRK2<sup>3ckw</sup> models using both the 3.47Å C3 and 3.8 Å density-subtracted maps. We used a combination of Rosetta<sup>58</sup> and manual building in Coot<sup>59</sup> to build all models. Starting models were found via a sequence alignment search in HHpred<sup>60</sup> and each section was built from the following: (1) The RoC and COR domains were built using the top two alignment results, 3DPT_B and 3DPU_B, which scored much higher than those ranked third and below; (2) The kinase N-lobe, kinase C-lobe, and WD40 domain were all built from the top five sequence matches: SGAA_A, 10PK_A, 4BTB_A, SGA_A, 5K00_A for the kinase N-lobe; SCYZ_A, 2IZR_A, SYKS_B, 3595_B, 4TWC_B for the kinase C-lobe; and 4J57_A, 30W8_C, 5U69_A, 5092_F, 5STA_B for the WD40 domain. The C-terminal helix was built manually. We built the COR-B, KIN, and WD40 domains using the density of the 3.47Å C3 map and the RoC and COR-A domains using the 3.8 Å map, then connected the two.
after fitting them into the 3.8Å map. Finally, we performed multiple iterations of both the CM and Relax functions in Rosetta, along with manual manipulation in Coot, to build our final 20 models (10 including GDP-Mg2+ in the RoC domain, and 10 excluding it). In areas of weak density, we either removed part of the polypeptide chain or, where only side chain density was poor, converted the chain to poly-alanine.

The GDP-Mg2+ was placed in our model by initially aligning a structure of the RoC domain containing a bound GDP-Mg2+ (PDB: 2zef) to the RoC domain in our structure. The GDP-Mg2+ was then added to our model in the aligned position and run through Rosetta to allow for fine movements into our density and re-arrangement of nearby chains.

The phosphorylation of the threonine residue 1343, which we observe in our map and is known a phosphorylation site of Roco family GTPases61, was confirmed by phosphor-enrichment mass spec (data not shown).

Electron microscopy sample preparation, imaging, and processing of apo, MLI-2, Ponatinib LRRK2<sub>hckw</sub> monomer/dimers. For all samples, purified LRRK2<sub>hckw</sub> was dialysed into the same final buffer as described for the trimer data, then diluted to its final concentration in the same buffer. Unlike with the trimer data, however, the following data sets were collected from multiple grids prepared using slightly different sample conditions and imaged using a range of microscope settings.

The apo LRRK2<sub>hckw</sub> monomer data set had sample diluted to final concentrations ranging between 1μM and 6μM. In addition, one data set was collected with the grid tilted to 30° to overcome preferred orientation issues. Otherwise, grids were prepared as described for the trimer data set.

The apo LRRK2<sub>hckw</sub> dimer data set had sample diluted to final concentrations ranging between 4μM and 12μM. Two of the samples contained 0.05mM Digitonin (Sigma, D141) or 0.03% octyl glucoside (Sigma, O8001) detergents to overcome preferred orientation issues. One data set was collected with the grid tilted to 30°, also to overcome preferred orientation issues. Otherwise, grids were prepared as described for the trimer data set.

The MLI-2 LRRK2<sub>hckw</sub> dimer data set had sample diluted to final concentrations of either 3μM or 4μM. MLI-2 was added post-dialysis to a final concentration of 5μM. The sample was incubated on ice for at least one hour before being applied to the grid. Otherwise, grids were prepared as described for the trimer data set.

The ponatinib LRRK2<sub>hckw</sub> dimer data set had sample diluted to final concentrations of 2μM or 4μM. Ponatinib was added post-dialysis at a concentration of either 5μM or 100μM. The sample was incubated on ice for at least one hour before being applied to the grid. Otherwise, grids were prepared as described for the trimer data set.

The apo LRRK2<sub>hckw</sub> monomer cryo-EM data was collected on a Talos Arctica (FEI) operated at 200kV, equipped with a K2 Summit direct electron detector (Gatan). Automated data collection was performed using Leginon<sup>48</sup>. A total of 11,354 movies were collected. We imaged samples at dose rates between 4.6 and 7.8 electrons Å<sup>-2</sup> sec<sup>-1</sup> with total exposure times ranging between 7 s and 11 s sub-divided into 200ms frames, for a total of 35 or 55 frames. All the images were recorded at a nominal magnification of 36,000x (either counting mode or super resolution mode) resulting in object pixel sizes of either 1.16Å or 0.58Å, respectively. The defocus range of the data was -1μm to -2μm.

Frame alignment, CTF estimation, image selection, and particle picking were performed as described for the apo LRRK2<sub>hckw</sub> monomer. After selection we had 3,100 micrographs. We carried out subsequent processing in CryoSpaRC2<sup>53</sup> on binned images (2.32Å pixel<sup>-1</sup>).

The classification and refinement scheme for the apo LRRK2<sub>hckw</sub> WD40- and COR-mediated dimer maps is shown in Extended Data Fig. 6. The same initial dimer references used for the apo LRRK2<sub>hckw</sub> monomer, filtered to the same resolution, were used here for refinement of the dimer maps. In addition, a linear trimer reference, generated by combining two initial dimer references and filtered to the same resolution, was used during the initial 3D classification step to sort out species longer than dimer, which negatively affected subsequent alignment. The final maps had resolutions of 13.39Å (WD40-mediated dimer) and 9.52Å (COR-mediated dimer) with C2 symmetry applied to both.

The MLI-2 LRRK2<sub>hckw</sub> dimer cryo-EM data was collected as described for the apo LRRK2<sub>hckw</sub> monomer. We recorded a total of 4,139 movies. We imaged all data sets in ‘counting mode’ at a dose rate of 5.5 electrons Å<sup>-2</sup> sec<sup>-1</sup>, with total exposure times of either 9 s or 10 s sub-divided into 200ms frames, for a total of 45 or 50 frames. All the images were recorded at a nominal magnification of 36,000x (counting mode) resulting in object pixel sizes of 1.16Å. The defocus range of the data was -1μm to -2μm.

Frame alignment, CTF estimation, image selection, and particle picking were performed as described for the apo LRRK2<sub>hckw</sub> monomer. After selection, 4,030 micrographs were kept for further processing. Processing was done in Relion 3.0<sup>52</sup> then CryoSparc2<sup>53</sup> using binned images (2.32Å pixel<sup>-1</sup>).

The classification and refinement scheme for the MLI-2 LRRK2<sub>hckw</sub> WD40- and COR-mediated dimer maps is shown in Extended Data Fig. 5. The same references used for the apo LRRK2<sub>hckw</sub> dimers, and filtered to the same resolution, were used here for the same purposes. The final maps had resolutions of 9.74Å (WD40-mediated dimer) and 9.04Å (COR-mediated dimer), with no symmetry applied.

The Ponatinib LRRK2<sub>hckw</sub> dimer cryo-EM data was collected as described for the apo LRRK2<sub>hckw</sub> monomer. We recorded a total of 1,797 movies. We imaged all data sets at dose rates of either 5.5 or 9.7 electrons Å<sup>-2</sup> sec<sup>-1</sup> with total exposure times of either 7 s or 10 s sub-divided into 200ms frames, for a total of 35 or 50 frames. All the images were recorded at a nominal magnification of 36,000x (counting mode) resulting in object pixel sizes of 1.16Å. The defocus range of the data was -1μm to -2μm.

Frame alignment, CTF estimation, image selection, and particle picking were performed as described for the apo LRRK2<sub>hckw</sub> monomer. 1,455 micrographs were kept for further processing. Processing was done in Relion 3.0<sup>52</sup> then CryoSparc2<sup>53</sup> using binned images (2.32Å pixel<sup>-1</sup>).

Electron microscopy sample preparation and imaging of microtubule-associated LRRK2<sub>hckw</sub>. Purified LRRK2<sub>hckw</sub> and unpolymerized bovine tubulin were added together to the microtubule
Docking of LRRK2<sup>BCxW</sup> into cryo-EM maps of monomers and dimers

In order to build models of WD40- and COR-mediated dimers of LRRK2<sup>BCxW</sup> in the presence of MLI-2, we again split LRRK2<sup>BCxW</sup> at the junction between the N- and C-lobes (L1949-A1950). The two halves were fitted into one half of the cryo-EM map of a WD40-mediated dimer of LRRK2<sup>BCxW</sup> obtained in the presence of MLI-2 (we chose this map as its resolution was higher than that of the COR-mediated dimer). We also docked the two halves of LRRK2<sup>BCxW</sup> into a cryo-EM map of a LRRK2<sup>BCxW</sup> monomer obtained in the absence of inhibitor. The fitting was done in Chimera<sup>44</sup> using the Fit in Map function with the options of filtering the structure to the resolution of the map and optimizing correlation. The two halves were then joined to generate a full model of LRRK2<sup>BCxW</sup>.

The WD40- and COR-mediated dimers of LRRK2<sup>BCxW</sup> in the presence of MLI-2 were built by docking the models built above into the corresponding cryo-EM maps, using the same approach in Chimera<sup>44</sup> as outlined above.

The LRRK2<sup>BCxW</sup> “filament” shown in Extended Data Fig. 7f was generated by aligning, in alternating order, multiple copies of the two dimer models (WD40- and COR-mediated) built into the cryo-EM maps obtained in the presence of MLI-2.

Kinase inhibitors

Stocks of the kinase inhibitors MLI-2 (10 mM; Tocris), Ponatinib (10 mM; ApexBio), GZD-924 (10 mM; Cayman Chemical), and LRRK2-1N-1 (2 mM; Michael J Fox Foundation) were stored in DMSO at -20 °C.

Antibodies

All antibodies used for immunocytchemistry were diluted to 1:500. Primary antibodies used were chicken anti-GFP (Aves Labs) and rabbit anti-alpha-tubulin (Proteich). Secondary antibodies used were goat anti-chicken-Alexa 488 (ThermoFisher) and goat anti-chicken Alexa568 (ThermoFisher). DAPI was used at 1:5000 according to the manufacturers suggestions (ThermoFisher). Primary antibodies used for western blots were mouse anti-GFP (Santa Cruz, 1:1000 dilution) mouse anti-GAPDH (ProteinTech, 1:5000 dilution) and mouse anti-gamma-tubulin (ProteinTech, 1:5000 dilution). Secondary antibodies (1:15,000) used for western blots were IRDye goat anti-mouse 680RD and IRDye goat anti-rabbit 780RD (Li-COR).

Rab8a expression and purification

N-terminally tagged (His<sub>6</sub>-Zz) Rab8a containing a TEV cleavage site was cloned into a PET28a expression vector and expressed in BL21(DE3) E. coli cells. Transformed cells were grown overnight at 37 °C in 10 mL LB medium containing kanamycin (50 μg/mL), then diluted into 200 mL LB medium containing kanamycin (50 μg/mL), grown to an optical density at 600 nm of ~1-2, diluted into 4 L LB medium containing kanamycin (50 μg/mL), and grown to an optical density at 600 nm of 0.4. IPTG was added (final concentration 0.5 mM) to induce protein expression for 18 h at 18 °C. Cells were harvested by centrifugation at 9833 × g for 10 min at 4 °C, followed by resuspension in 15 mL LB medium and centrifugation at 2862 × g for 10 min at 4 °C. The cell pellet was flash frozen in liquid nitrogen and stored at -80 °C. For a typical protein purification, cell pellets were resuspended in lysis buffer (50 mM HEPES pH 7.4, 200 mM NaCl, 2 mM DTT, 10% glycerol, 5 mM MgCl<sub>2</sub>), 0.5 mM Pefabloc, and protease inhibitor cocktail tablets) and lysed by sonication on ice. The lysate was clarified by centrifugation at 164,700 × g for 40 min at 4 °C and then incubated with Ni-NTA agarose beads (Qiagen) for 1 h at 4 °C. Beads were extensively washed with wash buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 2 mM DTT, 10% glycerol, 5 mM MgCl<sub>2</sub>; His<sub>6</sub>-Zz-Rab8a was eluted in 40 mL elution buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 300 mM imidazole, 2 mM DTT, 10% glycerol, 5 mM MgCl<sub>2</sub>). The protein eluate was diluted twofold in wash buffer, incubated with IgG sepharose 6 fast flow beads equilibrated in wash buffer, incubated at 4 °C for
μL of release buffer (80 mM PIPES, 2 mM MgCl₂, 1 mM EGTA, and 300 mM NaCl) yielded ~0.5 to 1 μM K560-GFP dimer.

Supplied with 660 mM sucrose and flash frozen. A typical kinesin prep was incubated with motor solution in the dark for 5 min and warmed to room temperature (RT). For microtubule solution was incubated with 1 mM AMP-PNP and 20 μM taxol on ice to microtubule bind and release purification. A total of 1 mL motor was exchanged on a PD-10 desalting column (GE Healthcare) equilibrated with storage buffer (80 mM PIPES, 2 mM MgCl₂, 1 mM EGTA, and 0.2 M TCEP, 1 mM ATP, 200 μM GDP). 34 μL reaction mixtures containing kinase inhibitor or an equivalent volume DMSO were incubated at 30 °C, and samples were taken at 45 min, and 90 min. An effective reaction volume of 0.75 μL was run on a 4-12% Bis-Tris protein gel, and blotted with a commercially available antibody to pT72-Rab8a (M1O7-pRab8a) as previously described and per manufacturer’s instructions, with the exception that HRP-labelled secondary antibody was used at a dilution of 1:2000.

**Purification of molecular motors**

Protein purification steps were done at 4 °C unless otherwise indicated. Human KIF5B (K560-GFP) was purified from E. coli using an adapted protocol previously described. PET17b-KIF5b (K560)-GFP-His was transformed into BL21(DE3) RIPL cells (New England Biolabs) until OD 0.6-0.8 and expression was induced with 0.5 mM IPTG for 16 h at 18 °C. Frozen pellets from 2L culture were resuspended in 40 mL lysis buffer (50 mM Tris, 300 mM NaCl, 5 mM MgCl₂, and 0.2 M sucrose, pH 7.5) supplemented with 1 Complete EDTA-free protease inhibitor cocktail table (Roche) per 50 mL and 1 mg/mL lysozyme. The resuspension was incubated on ice for 30 min and lysed by sonication. Sonicate was exchanged on a PD-10 desalting column (GE Healthcare) equilibrated with wash buffer containing 2 mg/mL 3xFlag peptide. The eluate was concentrated to 0.02-0.1 mg/mL using a 100K MWCO concentrator (EMD Millipore) in a tabletop centrifuge and diluted to 2 mL in Buffer A (50 mM Tris-HCl [pH 8.0], 2 mM MgOAc, 1 mM EGTA, and 1 mM DTT) and injected onto a MonoQ 5/50 GL column (GE Healthcare and Life Sciences) at 1 mL/min. The column was pre-washed with 10 column volumes (CV) of Buffer A, 10 CV of Buffer B (50 mM Tris-HCl [pH 8.0], 2 mM MgOAc, 1 mM EGTA, 1 mM DTT, 1 mM KOAc) and again with 10 CV of Buffer A at 1 mL/min. To elute, a linear gradient was run over 26 CV from 35–100% Buffer B. Pure dynactin complex eluted from ~75–80% Buffer B. Peak fractions containing pure dynactin complex were pooled, buffer exchanged into a GF150 buffer supplemented with 10% glycerol, concentrated to 0.02-0.1 mg/mL using a 100K MWCO concentrator (EMD Millipore) and flash frozen in liquid nitrogen. Typical dynactin prep yields are between 150-300 nM.

**In vitro phosphorylation of Rab8a by LRRK2**

 Purified Rab8a (-3.8 μM) was phosphorylated by LRRK2 (38 μM) in a buffer containing 50 mM HEPES pH 7.4, 50 mM NaCl, 10 mM MgCl₂, 0.5 mM TCEP, 1 mM ATP, 200 μM GDP). 34 μL reaction mixtures containing kinase inhibitor or an equivalent volume DMSO were incubated at 30 °C, and samples were taken at 45 min, and 90 min. An effective reaction volume of 0.75 μL was run on a 4-12% Bis-Tris protein gel, and blotted with a commercially available antibody to pT72-Rab8a (M1O7-pRab8a) as previously described and per manufacturer’s instructions, with the exception that HRP-labelled secondary antibody was used at a dilution of 1:2000.

Human dynactin was purified from stable cell lines expressing an IC2-SNAP-3xFlag as described previously. Frozen pellets collected from ~60-100 × 15 cm plates were resuspended in dynactin lysis buffer (25 mM HEPES pH 7.4, 50 mM KOAc, 2 mM MgOAc, 1 mM EGTA, 10% glycerol (v/v), and 1 mM DTT) supplemented with 0.1 mM Mg-ATP, 0.5 mM Pefabloc and 0.02% Triton X-100, 100 μL of wash buffer supplemented with 250 mM potassium acetate, and again with 100 μL of wash buffer. Dynactin was eluted from beads with 1 mL of elution buffer (wash buffer with 2 mg/mL of 3xFlag peptide). The eluate was collected, filtered by centrifuging with Ultrafree-MC VV filter (EMD Millipore) in a tabletop centrifuge and diluted to 2 mL in Buffer A (50 mM Tris-HCl [pH 8.0], 2 mM MgOAc, 1 mM EGTA, and 1 mM DTT) and injected onto a MonoQ 5/50 GL column (GE Healthcare and Life Sciences) at 1 mL/min. The column was pre-washed with 10 column volumes (CV) of Buffer A, 10 CV of Buffer B (50 mM Tris-HCl [pH 8.0], 2 mM MgOAc, 1 mM EGTA, 1 mM DTT, 1 mM KOAc) and again with 10 CV of Buffer A at 1 mL/min. To elute, a linear gradient was run over 26 CV from 35–100% Buffer B. Pure dynactin complex eluted from ~75–80% Buffer B. Peak fractions containing pure dynactin complex were pooled, buffer exchanged into a GF150 buffer supplemented with 10% glycerol, concentrated to 0.02-0.1 mg/mL using a 100K MWCO concentrator (EMD Millipore) and flash frozen in liquid nitrogen. Typical dynactin prep yields are between 150-300 nM.

Human dynein was purified from stable cell lines expressing an IC2-SNAP-3xFlag as described previously. Frozen pellets collected from ~60-100 × 15 cm plates were resuspended in dynactin lysis buffer (25 mM HEPES pH 7.4, 50 mM KOAc, 2 mM MgOAc, 1 mM EGTA, 10% glycerol (v/v), and 1 mM DTT) supplemented with 0.1 mM Mg-ATP, 0.5 mM Pefabloc and 0.02% Triton X-100, 100 μL of wash buffer supplemented with 250 mM potassium acetate, and again with 100 μL of wash buffer. Dynactin was eluted from beads with 1 mL of elution buffer (wash buffer with 2 mg/mL of 3xFlag peptide). The eluate was collected, filtered by centrifuging with Ultrafree-MC VV filter (EMD Millipore) in a tabletop centrifuge and diluted to 2 mL in Buffer A (50 mM Tris-HCl [pH 8.0], 2 mM MgOAc, 1 mM EGTA, and 1 mM DTT) and injected onto a MonoQ 5/50 GL column (GE Healthcare and Life Sciences) at 1 mL/min. The column was pre-washed with 10 column volumes (CV) of Buffer A, 10 CV of Buffer B (50 mM Tris-HCl [pH 8.0], 2 mM MgOAc, 1 mM EGTA, 1 mM DTT, 1 mM KOAc) and again with 10 CV of Buffer A at 1 mL/min. To elute, a linear gradient was run over 26 CV from 35–100% Buffer B. Pure dynactin complex eluted from ~75–80% Buffer B. Peak fractions containing pure dynactin complex were pooled, buffer exchanged into a GF150 buffer supplemented with 10% glycerol, concentrated to 0.02-0.1 mg/mL using a 100K MWCO concentrator (EMD Millipore) and flash frozen in liquid nitrogen. Typical dynactin prep yields are between 150-300 nM.

**Human NINL** was purified as previously described. pET28a-2Z-TEV-Halo-NINL was transformed into BL21(DE3) cells (New England Biolabs) until OD 0.4-0.6 and expression was induced with 0.1 mM IPTG for 16 h at 18 °C. Frozen cell pellets from 1 L culture were resuspended in 40 mL of activator-lysis buffer (30 mM HEPES...
Article

[pH 7.4]. 50 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 1 mM DTT, 0.5 mM Pefabloc, 10% (v/v) glycerol) supplemented with 1 cComplete EDTA-free protease inhibitor cocktail per 50 mL and 1 mg/mL lysozyme. The resuspension was incubated on ice for 30 min and lysed by sonication. The lysate was clarified by centrifuging at 66,000 × g for 30 min in Type 70 Ti rotor (Beckman). The clarified supernatant was incubated with 2 mL of packed IgG Sepharose 6 Fast Flow beads (GE Healthcare Life Sciences) for 2 h on a roller. The beads were transferred to a gravity flow column, washed with 100 mL of activator-lysis buffer supplemented with 150 mM potassium acetate and 30 mL of cleavage buffer (50 mM Tris-HCl [pH 8.0], 150 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 1 mM DTT, 0.5 mM Pefabloc, 10% (v/v) glycerol). The beads were then resuspended and incubated in 15 mL of cleavage buffer supplemented with 0.2 mg/mL TEV protease overnight on a roller. The supernatant containing cleaved proteins were concentrated using a 50K MWCO concentrator (EMD Millipore) to 1 mL, filtered by centrifuging with Ultrafree-MC VV filter (EMD Millipore) in a tabletop centrifuge, diluted to 2 mL in Buffer A (30 mM HEPES [pH 7.4], 50 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 10% (v/v) glycerol and 1 mM DTT) and injected onto a MonoQ 5/50 GL column (GE Healthcare and Life Sciences) at 0.5 mL/min. The column was pre-washed with 10 CV of Buffer A, 10 CV of Buffer B (30 mM HEPES [pH 7.4], 1 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 10% (v/v) glycerol and 1 mM DTT) and again with 10 CV of Buffer A at 1 mL/min. To elute, a linear gradient was run over 26 CV from 0–100% Buffer B. The peak fractions containing unlabelled Halo-tagged NINL were collected and concentrated to using a 50K MWCO concentrator (EMD Millipore) to 0.2 mL. A typical NINL prep yield was ~5-10 μM dimer.

Single-molecule microscopy and motility assays

Single-molecule imaging was performed using total internal reflection fluorescence (TIRF) microscopy with an inverted microscope (Nikon, Ti-E Eclipse) equipped with a 100x 1.49 N.A. oil immersion objective (Nikon, PlanApo), and a Multifocal Laser Line (Agilent), with 405 nm, 488 nm, 561 nm and 640 nm laser lines. Excitation and emission paths were filtered using single bandpass filter cubes (Chroma), and emitted signals were detected with an electron multiplying CCD camera (Andor Technology, iXon Ultra 888). Illumination and image acquisition were controlled with NIS Elements Advanced Research software (Nikon), and the xy position of the stage was controlled with a ProScan linear motor stage controller (Prior).

Single-molecule motility were performed in flow chambers as previously described23 using the setup shown in the schematic in Fig. 4A. Biotin-PEG-functionalized coverslips (Microsurfaces) were adhered to a Superfrost Plus Microscope slide (ThermoFisher) using polyethylenimine (PEI, Polysciences). After 48 h, cells were treated for 30 min with either 5 μM GZD-824 or DMSO-matched control. Cells were lysed on ice in RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.2% Triton X-100, 0.1% SDS, 0.5% Na-Deoxycholate, with cComplete protease inhibitor cocktail). Lysates were further rotated for 15 min at 4°C and clarified by centrifuging at 13,000 × g for 15 min. Clarified supernatants were boiled for 5 min in Laemmli buffer. The experiments were performed in triplicate.

For western blots, lysates were run on 4–12% gradient SDS–PAGE (Life Technologies) for 60 min and transferred to nitrocellulose for 3 h at 250 mA. Blots were dried at RT for 30 min, rinsed in 1x Tris buffered saline (TBS), followed by blocking with 5% milk in TBS. Antibodies were diluted in 5% milk in TBS-0.1% Tween-20 (TBST). Primary antibodies were incubated overnight at 4°C and Infrared (IR) secondary antibodies were incubated at RT for 45 min. For quantification of LRRK2 expression levels, blots were imaged on an Odyssey CLx controlled by Imaging Studio software (v5.2). DMSO and GZD-824 conditions were quantified in triplicate and normalized to a GAPDH loading control using Empiria Studio software (LI-COR). To ensure quantification was in the combined linear range for antibodies detecting both GFP-LRRK2 and GAPDH, a linear dilution series of lysates from cells expressing GFP-LRRK2 was also quantified by IR western blot.
Immunofluorescence, confocal microscopy and image analysis
The day before transfection, 293T cells were plated on acid-treated coverslips (Belco Glass) pre-coated with 100 µg/ml Poly-D-lysine (Sigma) and 4 µg/ml Mouse Laminin (ThermoFisher) in 24-well plates (35K cells per well). Cells were transfected with 500 ng plasma of either pDEST53-GFP-LRRK2 or pDEST53-GFP-LRRK2(2020T) using PEI. After 48-72 h, cells were incubated with either a kinase inhibitor or DMSO-matched control (matched for time and concentration). For the Type I inhibitor experiment, cells were incubated with DMSO or Mli-2 (500 nM) for 2 h. For the Type II inhibitor, cells were incubated with DMSO or GZD-824 (5 or 10 µM) for 30 min. Cells were quickly washed 1x on ice with ice-cold PBS, and fixed with ice-cold 4%PTA/90% Methanol/5mM sodium bicarbonate for 10 min at 20 °C. Following fixation, the wells were immediately washed 3x with ice-cold PBS. Blocking buffer (1% BSA, 5% normal goat serum, 0.3% Triton-X100 in PBS) was added for 1h at RT. Primary antibodies were diluted (1:500) in antibody dilution buffer (1% BSA, 0.1% Triton-X100 in PBS) and incubated overnight at 4 °C. After overnight incubation, the wells were washed 3x in PBS and incubated with secondary antibodies (1:500) in antibody dilution buffer for 1h at RT. After secondary incubation, the wells were washed 3x in PBS, 1x in ddH2O and mounted using Citifluor AF2 (EMS) on Superfrost Plus Microscope slides (ThermoFisher). Coverslips were sealed with nail polish and stored at 4 °C.

For the LRRK2 filament analysis in Fig. 5, experimenters were blinded to condition for both the imaging acquisition and analysis. Cells were imaged using a Nikon A1R HD confocal microscope with a LUN-V laser engine (405nm, 488nm, 561nm, and 640nm) and DU4 detector using bandpass and longpass filters for each channel (450/50, 525/50, 595/50, and 700/75). Slides were imaged on a Nikon Ti2 body using an Apo 60x 1.49 NA objective. Image stacks were acquired in resonant scanning mode with bidirectional scanning and 4x line averaging and 1.2 airy units. The lasers used were 405nm, 488nm and 561nm. Illumination and image acquisition were controlled by NIS Elements Advanced Research software (Nikon Instruments). ImageJ was used to quantify the percent of cells with LRRK2 filaments. Maximum-intensity projections were generated from z-stack confocal images. Using the GFP immunofluorescence signal, transfected cells were traced. Cells were scored for the presence or absence of filaments using both the z-projection and z-stack micrographs as a guide. The presence of filaments was scored if the cells had either (a) a GFP filament signal greater than 5 µm or (b) bundles of filaments with at least two identifiable crosses. To calculate the percent cells with filaments, the number of cells with filaments was divided by the total number of transfected cells per technical replicate (defined as one 24-well coverslip). Approximately 20 cells were quantified per replicate for each condition in Fig. 5D (DMSO vs. Mli-2) and between 40-100 cells were quantified per replicate for each condition in Fig. 5F (DMSO vs. GZD-824). The quantification of all cellular experiments comes from data collected on three separate days except for the 10 µM GZD-824 condition in Fig. 5F which was performed on two separate days. All statistical analyses were performed in Prism8 (Graphpad).

Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

Data availability
All reagents and data will be made available upon request. Model coordinates for the LRRK2<sub>2kxw</sub> structure are deposited in the Protein Data Bank (PDB) as follows: (1) PDB accession code 6VP6: LRRK2<sub>2kxw</sub> with the adjacent COR-B and WD40 domains (from the trimer) used to optimize residues at those interfaces during refinement in Rosetta, with GDP-Mg<sup>2+</sup> bound; (2) PDB accession code 6VNO: The top 10 models for LRRK2<sub>2kxw</sub> without adjacent domains, with GDP-Mg<sup>2+</sup> bound; (3) PDB accession code 6VP8: LRRK2<sub>2kxw</sub> with the adjacent COR-B and WD40 domains (from the trimer) used to optimize residues at those interfaces during refinement in Rosetta, no GDP-Mg<sup>2+</sup>; (4) PDB accession code 6VP7: The top 10 models for LRRK2<sub>2kxw</sub> without adjacent domains, no GDP-Mg<sup>2+</sup> bound. Cryo-EM maps for the different LRRK2<sub>2kxw</sub> structures are deposited at the EMDB as follows: (1) EMDB accession code 21250: This deposition contains both the 3.5Å map of LRRK2<sub>2kxw</sub> (trimer used to build the COR-B, kinase and WD40 domains) and the 3.8Å map of the signal-subtracted LRRK2<sub>2kxw</sub> (trimer used to build the RoC and COR-A domains); (2) PDB accession code 21306: 8.1Å map of LRRK2<sub>2kxw</sub> monomer; (3) EMDB accession code 21309: 9.5Å map of COR-mediated LRRK2<sub>2kxw</sub> dimer in the absence of kinase ligand ("apo"); (4) EMDB accession code 21310: 13.4Å map of WD40-mediated LRRK2<sub>2kxw</sub> dimer in the absence of kinase ligand ("apo"); (5) EMDB accession code 21311: 9.0Å map of COR-mediated LRRK2<sub>2kxw</sub> dimer in the presence of MLi-2; (6) EMDB accession code 21312: 10.2Å map of WD40-mediated LRRK2<sub>2kxw</sub> dimer in the presence of MLi-2. Source data for E10 are provided with the paper. All other data that support the findings of this study are available from the corresponding authors upon reasonable request.

Acknowledgements
We thank Susan Taylor for her role in initiating this collaborative work, which was partially supported by multi-investigator grants from the Michael J Fox Foundation: grant number 15247 to R.D., P. Sung, and B. Henderson (NIH Grant T32 GM008326) and the Molecular Biophysics Training Grant (NIH Grant T32 GM008326) and the Molecular Biophysics Training Grant (NIH Grant T32 GM008326) and the Molecular Biophysics Training Grant (NIH Grant T32 GM008326) and the Molecular Biophysics Training Grant (NIH Grant T32 GM008326).
subsequently by a Predoctoral Fellowship from the Visible Molecular Cell Consortium and Center for Trans-scale Structural Biology (UC San Diego). DS is supported by an A.P. Giannini Foundation postdoctoral fellowship. AKS receives salary and support from the Ludwig Institute for Cancer Research. EV is supported by a NIH Director’s New Innovator Award DP2GM123494. SLR-P is an investigator of the Howard Hughes Medical Institute and is also supported by R01GM121772. AEL is supported by R01GM107214. SK is grateful for support from the SGC, a registered charity that receives funds from Abbvie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative EU-BOPEN (agreement No 875510), Janssen, Merck KGaA, MSD, Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and the Wellcome, as well as Boehringer Ingelheim for funding initial structural studies of this project. Most of this work is described in the thesis by C.K.D. (https://escholarship.org/content/qt95k5q45v/qt95k5q45v.pdf?tr=q87k9q). 

Author contributions CKD collected and processed the cryo-EM data. JS performed the single-molecule and cellular assays with the help of OD. SM designed the LRRK2RCKW construct and purified the protein. CKD and IL built the molecular model of LRRK2RCKW. DS performed the SEC-MALS and phosphorylation assays. MM collected and analyzed the LRRK2RCKW and microtubule cryo-EM data. RW and JB performed the cellular cryo-ET. AKS contributed to the structural analysis and provided advice on the selection of kinase inhibitors. SK, EV, SLR-P and AEL directed and supervised the research. CKD, JS, SLR-P and AEL wrote the manuscript and SM, DS, MM, OD, AKS, SK and EV edited it.

Competing interests The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41586-020-2673-2.

Correspondence and requests for materials should be addressed to S.L.R.-P. or A.E.L.

Peer review information Nature thanks Asa Abelovich, Henning Stahlberg and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at http://www.nature.com/reprints.
Extended Data Fig. 1 | Optimization of LRRK2 constructs and cryo-EM analysis of a LRRK2^RCKW trimer. a, We systematically scanned domain boundaries (amino acid numbers of boundaries noted above domain names) to generate LRRK2 constructs that expressed well in baculovirus-infected insect cells and yielded stable and soluble protein. These attempts included full-length LRRK2, the kinase domain alone or with the WD40 domain, and other isolated domains. In this approach, only the GTPase domain on its own expressed well. Next, we gradually shortened LRRK2 from its amino terminus. Red asterisks indicate constructs that were soluble. b, After identifying domain boundaries yielding constructs that expressed soluble protein, additional fine tuning of boundaries was performed. A Coomassie stained SDS–PAGE gel shows systematic N-terminal truncations at the RoC domain resulting in the identification of a construct with the highest expression levels: amino acids 1327 to 2527 (red asterisk, "LRRK2^RCKW" here). c, A Coomassie stained SDS–PAGE gel of purified LRRK2^RCKW after elution from an S200 gel filtration column. As predicted by its primary structure, LRRK2^RCKW runs at ~140 kDa. d, Electron micrograph of LRRK2^RCKW. e, 2D class averages of the LRRK2^RCKW trimer. f, 2D/3D classification scheme used to obtain the 3.5Å structure of the LRRK2^RCKW trimer. g, h, Fourier Shell Correlations (from CryoSparc) (d) and Euler angle distribution (e) for the LRRK2^RCKW trimer.
Extended Data Fig. 2 | See next page for caption.
Extended Data Fig. 2 | Cryo-EM analysis of a signal-subtracted LRRK2<sub>RckW</sub> trimer and map-to-model fit. a, Processing strategy used to obtain a 3.8Å structure of LRRK2<sub>RckW</sub> generated from a signal-subtracted trimer where only one monomer contains the RoC and COR-A domains. This structure improved the resolution of the RoC and COR-A domains relative to the full trimer (Extended Data Fig. 1). b–d, 2D class averages (b), Fourier Shell Correlations (from Relion) (c), and Euler angle distribution (from Relion) (d) for the 3.8Å-resolution signal-subtracted LRRK2<sub>RckW</sub> structure. e, Close-ups (f–l) of different parts of the final model fit into the map. f, Section of the WD40 domain. g, C-terminal helix and its interface with the kinase domain. h, Active site of the kinase. Residues in the DYG motif are labelled. G2019, the site of a major PD-associated mutation (G2019S) and the last residue of the activation loop seen in our structure, is highlighted by a black rounded square. i, Interface between COR-B and the αC helix of the N-lobe of the kinase domain. j, Interface between the RoC and COR-B domains. R1441 and Y1699, two residues mutated in PD, are labelled. k, l, Two different views of the RoC and COR-A domains with GDP-Mg<sup>2+</sup> modelled into the density. Side chains were omitted in these two panels, corresponding to the lowest-resolution parts of the map. m, Map-to-model FSC plots for the top-ranked LRRK2<sub>RckW</sub> models, with (left) or without GDP-Mg<sup>2+</sup> (right) in the RoC domain. The 0.143 FSC values are reported in Supplementary Table 1. n, Size Exclusion Chromatography-Multiple Angle Light Scattering (SEC-MALS) analysis of LRRK2<sub>RckW</sub> under the conditions used for cryo-EM (Fig. 1). The table shows the calculated molecular weights (MW) of LRRK2<sub>RckW</sub> according to SEC standards ("SEC") and MALS.
Extended Data Fig. 3 | See next page for caption.
Extended Data Fig. 3 | Comparisons between LRRK2 and other kinases and modelling of the Leucine-Rich Repeat (LRR) into LRRK2\(^{\text{RCKW.}}\) 

a, View of the LRRK2\(^{\text{RCKW}}\) atomic model with COR-A, COR-B and kinase domains colored. The N- and C-lobes of the kinase are labelled, as is the αC helix in the N-lobe. 
b, c, The FAK-FERM (PDB: 2J0J)\(^{17}\) (b) and CDK2-Cyclin A (PDB: 2CCH)\(^{19}\) (c) complexes, shown in the same orientation as the kinase in (a). The αC helix of CDK2 is also labelled. 
d, Same view as in (a) with only the kinase domain and the C-terminal helix colored. 
e, Rotated view of LRRK2’s kinase domain with the C-terminal helix facing the viewer. 
f, g, CDKL3 (PDB: 3ZDU) (f) and RIPK2 (PDB: 4C8B)\(^{32}\) (g) shown in the same orientation as LRRK2’s kinase in (e), with alpha helices with the same general location as LRRK2’s C-terminal helix colored in green. 
h, KSR2-MEK1 complex (PDB: 2Y4I), with the kinase oriented as in (e) (left) and after removing KSR2 for clarity (right). The alpha helix associated with the kinase is shown in green. 
i, HCK (PDB: 2HCK) in complex with its SH2 and SH3 domains with the kinase oriented as in (e) (left), and after removal of the SH2 and SH3 domains for clarity (right). A remaining alpha helix from the SH2 domain is shown in yellow. 
j, Front view of LRRK2’s kinase with the C-Spine and R-Spine residues colored in grey and white, respectively. 
k, Close-up of the DYG motif and neighbouring R-Spine residues. A putative hydrogen bond between Y2018 and the backbone carbonyl of I1933 is shown (O–O distance: 2.7Å). This interaction provides a structural explanation for the hyperactivation of the kinase resulting from a Y2018F mutation\(^{38}\), which would release the activation loop. 
l, Crystal structure of the LRR-RoC-COR(A/B) domains from C. tepidum Roco (PDB: 6HLU)\(^{7}\). 
m, Homology model for human LRR-RoC-COR(A/B) based on the C. tepidum Roco structure (from SWISS-MODEL). 
n, Chimeric model combining LRRK2\(^{\text{RCKW}}\) and the homology model for the LRR domain from (m) obtained by aligning their RoC-COR(A/B) domains. 
o, p, Two views of the hybrid LRRK2\(^{\text{RCKW}}\) model. 
q, Close-up showing the proximity between the active site of the kinase (with the side chains of its DYG motif shown) and the S1292 autophosphorylation site on the LRR. The close-up also highlights the proximity between N2081, a residue implicated in Crohn’s Disease, and the LRR.
Extended Data Fig. 4 | See next page for caption.
Extended Data Fig. 4 | Comparison between LRRK2 RCKW and integrative models built into cryo-ET maps of LRRK2 filaments in cells and docking of LRRK2 RCKW into those maps. a, Root-mean-square deviation (r.m.s.d.) between the atomic model of LRRK2 RCKW and each of the 1,167 integrative models generated by Watanabe, Buschauer, Bohning and colleagues. RMSDs were calculated in Chimera using 100% residue similarity and with pruning iterations turned off. r.m.s.d. values are grouped into 53 clusters of related models (see 5 for details), with the mean and standard deviation shown whenever the cluster contains two or more models. Integrative models that gave the lowest, median and highest r.m.s.d. values are shown. The models are colored according to the per-residue r.m.s.d. with the atomic model of LRRK2 RCKW. b, The WD40s in the crystal structure of a dimer of LRRK2's WD40 (PDB: 6DLP) were replaced with the WD40s from our cryo-EM structure of LRRK2 RCKW. c, The resulting dimer was fitted into the 14Å cryo-ET map of cellular microtubule-associated LRRK2 filaments. d, Two views of the same fitting shown in (c), displayed with a higher threshold for the map to highlight the fitting of the WD40 β-propellers into the density. The white arrows point towards the holes at the centre of the β-propellers densities. e, Four copies of LRRK2 RCKW were docked into the cryo-ET map by aligning their WD40 domains to the docked WD40 dimer. f, Model containing the four aligned LRRK2 RCKW. g-j, Modelling of the kinase-closed form of LRRK2 RCKW. g, h, The structure of ITK bound to an inhibitor (PDB: 3QGY), which is in a closed conformation, was aligned to LRRK2 RCKW using only the C-lobes of the two kinases. i, The N-terminal portion of LRRK2 RCKW, comprising RoC, COR-A, COR-B and the N-lobe of the kinase, was aligned to ITK using only the N-lobes of the kinases. RoC, COR-A and COR-B were moved as a rigid body in this alignment. j, Kinase-closed model of LRRK2 RCKW.
Extended Data Fig. 5 Ab initio models for cryo-EM of LRRK2\textsuperscript{RCKW} dimers and cryo-EM analysis of WD40- and COR-mediated dimers of LRRK2\textsuperscript{RCKW} in the presence of the inhibitor MLi-2. a, An initial data set was collected from a sample of LRRK2\textsuperscript{RCKW} incubated in the presence of the kinase inhibitor MLi-2 and dimers were selected. b, Representative two-dimensional class averages used for ab initio model building. c, Ab initio models with the structure of LRRK2\textsuperscript{RCKW} docked in. d, Volumes generated from the molecular models in (b), filtered to 30Å resolution. e, Projections of the volumes in (d) shown in the same order as their corresponding 2D class averages in (b). f, Data processing strategy for obtaining cryo-EM structures of WD40- and COR-mediated dimers of LRRK2\textsuperscript{RCKW} in the presence of the inhibitor MLi-2. The models used during this processing (see Methods) are those shown in (d) along with an additional linear trimer (see Methods) used for particle sorting.
Extended Data Fig. 6 | See next page for caption.
Extended Data Fig. 6 | Cryo-EM analysis of a monomer and WD40- and COR-mediated dimers of LRRK2RCKW in the absence of inhibitor (“Apo”) and dimerization of LRRK2RCKW outside the filaments. a, Data processing strategy for obtaining cryo-EM structures of a monomer and WD40- and COR-mediated dimers of LRRK2RCKW in the absence of inhibitor. The models used during the processing of the dimers (see Methods) are those shown in Extended Data Fig. 5d, along with an additional linear trimer (see Methods) used for particle sorting. The models used for processing of the monomer (see Methods) were the same dimer models as in Extended Data Fig. 5d (used for particle sorting) in addition to a monomer model generated from our LRRK2RCKW model (used for refinement).

b, Two-dimensional (2D) class averages of WD40- and COR-mediated LRRK2RCKW dimers obtained in the absence of inhibitors (“Apo”) or in the presence of either Ponatinib or MLi-2. The same molecular models of the two dimers shown in Fig. 3 are shown on the left but in orientations similar to those represented by the 2D class averages shown here. For each class average, a projection from the corresponding model in the best-matching orientation is shown to its left. c, Two copies of the LRRK2RCKW structure were aligned to the RoC-COR domains of the LRR-RoC-COR structure from C. tepidum’s Roco protein (PDB: 6HLU) to replicate the interface observed in the bacterial homologue in the context of the human protein. This panel shows a comparison between the dimer modelled based on the C. tepidum LRR-RoC-COR structure and the dimer observed for LRRK2RCKW in this work. While the bacterial structure shows a dimerization interface that involves the GTPase (RoC), LRRK2RCKW interacts exclusively through its COR-A and -B domains, with the RoC domains located away from this interface. The two arrangements are shown schematically in cartoon form below the structures.
Extended Data Fig. 7 | See next page for caption.
Extended Data Fig. 7 | Properties of the microtubule-associated LRRK2<sup>2RCKW</sup> filaments. a, b, The LRRK2<sup>2RCKW</sup> structure solved in this work (a) was split at the junction between the N- and C-lobes of the kinase domain (L1949–A1950) (b). c, Docking of the two halves of LRRK2<sup>2RCKW</sup> into a cryo-EM map of a LRRK2<sup>2RCKW</sup> dimer solved in the presence of MLi-2. The dimer map is the same one shown in Fig. 3 and Extended Data Figs. 10 and 11. d, The model obtained in (c) was docked into cryo-EM maps of either WD40- or COR-mediated dimers obtained in the presence of MLi-2. e, Molecular models resulting from the docking in (d). f, Aligning, in alternating order, copies of the dimer models generated in (d) results in a right-handed filament with dimensions compatible with those of a microtubule, and its RoC domains pointing inwards (see Fig. 3g–i for more details). g, Docking of the two halves of LRRK2<sup>2RCKW</sup> into a cryo-EM map of a LRRK2<sup>2RCKW</sup> monomer solved in the absence of inhibitor (“Apo”). The map is the one shown in Fig. 1h and Extended Data Fig. 6. h, Three-way comparison of LRRK2<sup>2RCKW</sup> (with domain colours) and the models resulting from the dockings into the MLi-2 WD40-mediated dimer map (c) (dark blue) and “Apo” monomer map (g) (light blue). The three structures were aligned using the C-lobes of their kinases and the WD40 domain. The superposition illustrates that the docking into the “Apo” map results in a structure very similar to that obtained from the trimer (Fig. 1) and that the presence of MLi-2 leads to a closing of the kinase. i, Molecular model of the microtubule-associated LRRK2<sup>2RCKW</sup> filament obtained by docking a fragment of a microtubule structure (PDB: 6O2S) into the corresponding density in the sub-tomogram average (Fig. 2a). j, Same view as in (i) with the models shown as surface representations colored by their Coulomb potential. k, l, “Peeling off” of the structure shown in (j), with the LRRK2<sup>2RCKW</sup> filament seen from the perspective of the microtubule surface (k) and the microtubule surface seen from the perspective of the LRRK2<sup>2RCKW</sup> filament (l). Note: the acidic C-terminal tubulin tails are not ordered in the microtubule structure and thus are not included in the surface charge distributions. The Coulomb potential coloring scale is shown on the right.
Extended Data Fig. 8 | Inhibition of motor motility by wild-type and I2020T LRRK2 RCKW.

**a**, Example kymographs showing that increasing concentrations of LRRK2 RCKW reduce kinesin runs.

**b**, Example kymographs showing that 25 nM LRRK2 RCKW reduces dynein runs.

**c**, Representative kymographs of kinesin motility in the presence or absence of WT and I2020T LRRK2 RCKW.

**d**, The percentage of motile kinesin events per microtubule in the absence of LRRK2 or in the presence of 25 nM WT or I2020T LRRK2 RCKW. Data are mean ± s.d. (n = 12 microtubules per condition quantified from two independent experiments). There is a significant difference between 0 nM and both 25 nM RCKW conditions (P < 0.0001), but no significant (ns) difference between the inhibitory effects of WT LRRK2 RCKW versus I2020T LRRK2 RCKW as calculated using the Kruskal–Wallis test with Dunn’s posthoc for multiple comparisons (compared to no LRRK2 RCKW).
Extended Data Fig. 9 | See next page for caption.
Extended Data Fig. 9 | Type II kinase inhibitors rescue kinesin and dynein motility.

a–e, Ponatinib is a Type II, “DFG out” inhibitor. a, Superposition of the structures of Ponatinib-bound RIPK2 (PDB: 4C8B) and IRAK4 (PDB: 6EG9). Ponatinib is shown in yellow, and the DYG motif residues are shown in white. b, c For comparison, the structures of (a) Rococ4 bound to LRRK2-IN-1 (PDB: 4YZM), a LRRK2-specific Type I, “DFG in” inhibitor, and (b) a model of Mitogen-activated kinase 1 (MAPK1) bound to MLi-2 (PDB: 5U6I), another LRRK2-specific Type I, “DFG in” inhibitor are shown. The inhibitor and DFG residues are colored as in (a). d, The structures in (a–c), as well as the kinase from LRRK2 RCKW are shown superimposed. The colour arrowheads point to the N-lobe’s β-sheet to highlight the difference in conformation between kinases bound to the two different types of inhibitors. Note that LRRK2<sup>2IC50</sup>’s kinase is even more open than the two Ponatinib-bound kinases. e, Rotated view of (d), now highlighting the position of the N-lobe’s αC helix. An additional alpha helix in the N-lobe of MAPK1 was removed from this view for clarity. f, The kinase inhibitors MLi-2 (1 μM), LRRK2-IN-1 (1 μM), Ponatinib (10 μM) and GZD-824 (10 μM) all inhibit LRRK2<sup>2IC50</sup>’s kinase activity in vitro compared to a DMSO control. A western blot using a phospho-specific antibody to Rab8a at the indicated time points is shown. g, A dose response curve showing the percentage of motile kinesin events per microtubule as a function of Ponatinib concentration with LRRK2<sup>2IC50</sup> (25 nM) or without LRRK2<sup>2IC50</sup>. Data are mean ± s.d. (from left to right; n = 12, 18, 16, 14, and 9 microtubules quantified from one experiment). ****P < 0.0001 (Kruskal–Wallis test with Dunn’s posthoc for multiple comparisons, compared to DMSO without LRRK2<sup>2IC50</sup>). h, Dose response curve of run lengths from data in (g) represented as a cumulative frequency distribution. From top to bottom: n = 654, 173, 584, 293, and 129 motile kinesin events. Mean decay constants (tau) ± confidence interval (CI) are (from top to bottom) 2.736 ± 0.113, 1.291 ± 0.181, 2.542 ± 0.124, 2.285 ± 0.134, and 1.653 ± 0.171. Representative kymographs of kinesin and dynein with DMSO or Type II inhibitors with or without LRRK2<sup>2IC50</sup>. j, The Type II kinase inhibitors Ponatinib and GZD-824 rescue kinesin run length, represented as a cumulative frequency distribution of run lengths with LRRK2<sup>2IC50</sup> (25 nM) or without LRRK2<sup>2IC50</sup>. From top to bottom: n = 893, 355, 507, 499, 524, and 529 runs from two independent experiments. Mean decay constants (tau) ± 95% CI are (from top to bottom) 2.070 ± 0.038, 0.8466 ± 0.091, 1.938 ± 0.065, 2.075 ± 0.07, 1.898 ± 0.065, and 1.718 ± 0.064. Data were resampled with bootstrapping analysis and statistical significance was established using a one-way ANOVA with Dunnett’s test for multiple comparisons. DMSO run lengths were significantly different (P < 0.0001) between conditions (0 vs. 25 nM RCKW). Ponatinib (0 vs. 25 nM RCKW) and GZD-824 (0 vs. 25 nM RCKW) were not significant. k, Same as in (j) but with dynein. From top to bottom: n = 659, 28, 289, 306, 254, and 339 runs from two independent experiments. Mean decay constants (tau) ± 95% confidence intervals; microns are 4.980 ± 0.147, 0.846 ± 0.415, 4.686 ± 0.142, 4.445 ± 0.172, 3.156 ± 0.09, 3.432 ± 0.188 (from top to bottom). Statistical significance as in (j) and run lengths were significantly different (P < 0.0001) between DMSO conditions (0 vs. 25 nM RCKW), and not significant for Ponatinib or GZD0824 conditions. The DMSO conditions are reproduced from Fig. 4f for comparison. l, Expression levels of GFP-LRRK2 (I2020T) in 293T cells treated with either DMSO or GZD-824 (5 μM). An Immunoblot with anti-GFP (LRRK2) and anti-GADPH (loading control), which is a representative image from three replicates, is shown. m, Quantification of GFP-LRRK2 (I2020T) expression levels from western blots similar to (l). Data are mean ± s.d. (n = 3 per condition). GZD-824 is not significantly different from the DMSO-treated control (Mann–Whitney test). n, 293T cells immunostained for tubulin showing that the microtubule architecture is not affected by GZD-824 or MLi-2 compared to DMSO treatment. See Supplementary Table 1 for all source data and replicate information.
Extended Data Table 1 | Cryo-EM data collection and model refinement statistics.

| Data Collection | Trimer Dataset | Monomer (Apo) Dataset | Dimers (Apo) Dataset | Dimers (MLi-2) Dataset |
|-----------------|----------------|-----------------------|---------------------|------------------------|
| Number of grids used | 1 | 10 | 3 | 2 |
| Microscope | Titan Krios | Talos Arctica | Talos Arctica | Talos Arctica |
| Camera | Gatan K2 | Gatan K2 | Gatan K2 | Gatan K2 |
| Camera Mode (Counting/Super-Res.) | C | C/3R | C/3R | C |
| Voltage (kV) | 300 | 200 | 200 | 200 |
| Magnification | 130,000 | 36,000 | 36,000 | 36,000 |
| Pixel size (Å/pixel) | 1.07 | 1.16/0.58 | 1.16/0.58 | 1.16 |
| Dose rate (e/Å² second) | 6.65 | 4.2-10 | 4.6-7.8 | 5.5 |
| Exposure time (s) | 8 | 6-12 | 7-11 | 9-10 |
| Total dose (e/Å²) | 53.2 | 50.4-60 | 50.6-54.6 | 49.5-55 |
| Number of frames | 40 | 30-60 | 35-55 | 45-50 |
| Defocus range (µm) | 1-1.8 | 1-2 | 1-2 | 1-2 |
| Micrographs collected (no.) | 3,824 | 11,354 | 5,303 | 4,139 |
| Initial particle number | 836,956 | 1,184,330 | 431,387 | 706,807 |
| Final particle number | 70,954* | 15,999 | 63,435* | 72,249* |
| Final Resolution (0.143) | 3.5*/3.8* | 8.1 | 13.4*/9.5* | 10.2*/9.0* |

**LRRK2RCKW Models** *(without GDP-Mg²⁺) (with GDP-Mg²⁺)*

| | Monomer w/interfaces | Top 10 Monomers** | Monomer w/interfaces | Top 10 Monomers** |
|-----------------|-----------------------|---------------------|-----------------------|---------------------|
| PDB | 6VP8 | PDB: 6VP7 | PDB: 6VP6 | PDB: 6VNO |
| EMD | EMD-21250 | EMD-21250 | EMD-21250 | EMD-21250 |

**Model Refinement**

| | Map-to-model resolution (0.143 FSC threshold) (Å) | Map B-factor (Å²) | Model Composition |
|-----------------|-------------------------------------------------|-------------------|--------------------|
| | 3.98 | -136 | Non-hydrogen atoms |
| | 3.98 | -136 | Protein Residues |
| | 3.98 | -136 | Ligands |
| | 3.98 | -136 | B-factors (Å²) |
| | 3.98 | -136 | Protein |
| | 3.98 | -136 | Ligand |
| | 3.98 | -136 | R.M.S. Deviations |
| | 3.98 | -136 | Bond length (Å) |
| | 3.98 | -136 | Bond angle (°) |
| | 3.98 | -136 | Validation |
| | 3.98 | -136 | Molprobity score |
| | 3.98 | -136 | Clash score |
| | 3.98 | -136 | Poor rotamers (%) |
| | 3.98 | -136 | Ramachandran |
| | 3.98 | -136 | Favorable (%) |
| | 3.98 | -136 | Allowed (%) |
| | 3.98 | -136 | Disfavored (%) |

The model refinement statistics are reported for four different types of models, two including GDP-Mg²⁺ in the RoC domain and two excluding it. In each case, we report statistics for two types of model: “Monomer w/interfaces” consists of a LRRK2RCKW monomer plus fragments from the neighboring monomers in the C3 trimer that were used during model building and refinement; “Top 10 Monomers” are the top-10 results from Rosetta Relax with the neighboring fragments removed after processing in Rosetta. PDB accession numbers for the models and the EMD code of the maps used for model building and refinement are indicated. EMD-21250 contains both the C3 map of the LRRK2RCKW trimer used to build the COR-B, kinase and WD40 domains and the signal-subtracted monomer used to build the RoC and COR-A domains. The final models reported here were refined into the signal-subtracted monomer map. (See Methods for details.) * C3 reconstruction. ** signal-subtracted monomer. * WD40-mediated dimer. * COR-mediated dimer. ** Numbers represent the average of the values for all 10 models.
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
- Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted. Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

For electron microscopy experiments, data was collected with Leginon. All the electron microscopy data collection software sources are referenced in the methods section. For light microscopy experiments, data was collected with Nikon Elements Software (commercially available). For Western blot, data was collected using Image Studio v5.2 (LI-COR).

Data analysis

For electron microscopy experiments, data was processed with Appion, GCTTF, MotionCor2, FindEM, Cryolo, Relion3, and Cryosparc2. All the electron microscopy data processing software sources are referenced in the methods section. For light microscopy experiments, data was analyzed with ImageJ and used to make image z-maximum projections and kymographs. Graphpad Prism8 were used for all statistical analysis of light microscopy data. For Western blots, data was quantified using EmpiriaStudio software (LI-COR).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

For electron microscopy experiments, maps and coordinates are deposited on the PDB and EMDB. No image sets or particle stacks will be made available. All the raw data that went into the biochemical and cell biological analyses for Figures 4 and 5 (and associated Extended Data Figures) were deposited in a spreadsheet with the manuscript.
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

For all experiments, we determined the sample size by following conventions in the field.

Data exclusions

For single molecule kinesin experiments, clear bright aggregates (less than 5% of runs) were excluded from the analysis, as these runs display longer run lengths than typical single-molecule kinesin runs (Brouhard, 2010, Methods Cell Biol). No conclusions change with the addition or exclusion of these aggregates, and we would be happy to provide the data without exclusion of aggregates if deemed necessary.

Replication

All single molecule experiments in Figure 4 and 5 (including dynein and kinesin data with or without drugs) were performed with at least two, but up to four technical replicates on different days (except EDF10g,h that was only performed with one technical replicate). Major findings with kinesin and dynein single molecule data have been confirmed by two different protein preps. All cellular data from Figure 5 was quantified from at least four, but up to ten technical replicates (defined in the Methods as at least 20 cells per coverslip) and independent experiments were performed on multiple days as outlined in the Methods section.

Randomization

This is not relevant. We have no data involving organisms or subjects that would require randomization.

Blinding

For the cell biology data in Fig 5c-f, experimenter was blinded to conditions for both the imaging acquisition and analysis of LRRK2 filaments.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

| n/a | Involved in the study |
|-----|----------------------|
| ☒   | Antibodies           |
| ☒   | Eukaryotic cell lines |
| ☒   | Palaeontology        |
| ☒   | Animals and other organisms |
| ☒   | Human research participants |
| ☒   | Clinical data        |

Methods

| n/a | Involved in the study |
|-----|----------------------|
| ☒   | ChIP-seq             |
| ☒   | Flow cytometry       |
| ☒   | MRI-based neuroimaging |

Antibodies

- Antibodies used: mouse anti-GFP (Santa Cruz, clone: B-2, Cat: sc-9996, Lot: ); chicken anti-GFP (AvesLabs, Cat: GFP-1010, Lot: GFP879484); rabbit anti-alpha-tubulin (ProteinTech, Cat: 11224-1-AP); mouse anti-GAPDH (ProteinTech, Cat: 60004-1-Ig)

Validation

All antibodies used are well-validated and highly-specific commercially available antibodies. For LICOR quantification, linear

Eukaryotic cell lines

Policy information about cell lines

- Cell line source(s): HEK293T used were from ATCC (CRL-3216)
- Authentication: ATCC authenticated
- Mycoplasma contamination: Every new cell line we receive is tested for mycoplasma before expanding and freezing. After thawing, each cell line is tested again. Once every three months, our lab tests all growing cells for mycoplasma as well. The cells we used in our experiments were last test on 10/16/19 and did not contain contamination.
- Commonly misidentified lines (See ICLAC register): None